Coverart for item
The Resource Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt

Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt

Label
Fusion protein technologies for biopharmaceuticals : applications and challenges
Title
Fusion protein technologies for biopharmaceuticals
Title remainder
applications and challenges
Statement of responsibility
edited by Stefan R. Schmidt
Contributor
Subject
Language
eng
Summary
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei
Member of
Cataloging source
DLC
Dewey number
615.7
Index
index present
LC call number
RM301.4
LC item number
.F87 2013
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
NLM call number
QU 450
http://library.link/vocab/relatedWorkOrContributorName
Schmidt, Stefan R
http://library.link/vocab/subjectName
  • Biopharmaceutics
  • Pharmaceutical biotechnology
  • Recombinant Fusion Proteins
  • Drug Carriers
  • Immunotoxins
  • Immunotoxins
  • Protein Engineering
  • Recombinant Fusion Proteins
  • MEDICAL
  • Biopharmaceutics
  • Pharmaceutical biotechnology
Label
Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt
Instantiates
Publication
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm
Control code
811850420
Extent
1 online resource
Form of item
online
Isbn
9781299241954
Lccn
2012040270
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Specific material designation
remote
System control number
(OCoLC)811850420
Label
Fusion protein technologies for biopharmaceuticals : applications and challenges, edited by Stefan R. Schmidt
Publication
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm
Control code
811850420
Extent
1 online resource
Form of item
online
Isbn
9781299241954
Lccn
2012040270
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Specific material designation
remote
System control number
(OCoLC)811850420

Library Locations

    • Curtis Laws Wilson LibraryBorrow it
      400 West 14th Street, Rolla, MO, 65409, US
      37.955220 -91.772210
Processing Feedback ...